Monday 13th January 2025 |
Text too small? |
TruScreen invited to present at WHO global AI collaboration meeting
• TruScreen presented to a World Health Organisation (WHO) global meeting to further the use of AI technologies for screening of cervical cancer
• The presentation by CEO, Marty Dillon is attached for the information of stakeholders
At the invitation of World Health Organisation (WHO) TruScreen Group Limited (NZX/ASX:TRU) presented at a WHO global AI collaboration meeting on 11 and 12 November 2024 in Edinburgh. The meeting investigated the further use of Artificial Intelligence (AI) technologies for cervical cancer screening.
TruScreen’s unique AI enabled technology was the only opto-electric tissue differentiating medical device company invited to participate.
This invitation followed on from the UNITAID Report that featured TruScreen as a technology, currently in commercial use, for the primary screening of cervical cancer. After years of clinical trials, TruScreen technology received recent recognition by peak Medical Organisations and national Government agencies including:
• the Chinese Obstetricians and Gynaecologists Association (COGA),
• the Chinese Society for Colposcopy and Cervical Pathology (CSCCP),
• the Vietnam Ministry of Health National Technical List,
• COFEPRIS, the Mexican public health regulator, and
• The Russia Cervical Cancer Screening Guidelines.
TruScreen Chair, Mr Tony Ho commented:
“This WHO invitation was significant for TruScreen, and signals that, along with the recent recognition by national government agencies and peak Medical Organisations, that WHO recognises the use of TruScreen’s unique AI enabled opto-electric technology to reduce the preventable deaths of women from cervical cancer.
This is particularly relevant in TruScreen’s target markets – countries with limited or no cervical cancer screening programs, that resulted in high cervical cancer mortality rates. Ninety percent (90%) of cervical cancer deaths worldwide occur in these countries.”
This announcement has been approved by the Board.
Ends
No comments yet
TWR - Capital Return - ATO Class Ruling Obtained
THL - FY25 Trading Update
April 17th Morning Report
EBOS announces opening of Retail Offer
MCY - FY2025 EBITDAF guidance revised to $760m
April 16th Morning Report
AIA - March 2025 Monthly traffic update
Ryman Healthcare FY25 full year results and webcast detail
CHI - Q1 2025 Operational Update
CNU - Q3 FY25 Connections Update